Press Release Details

Know more. Learn how we have improved our Innatal® Prenatal Screen.

Progenity is dedicated to continuous product improvement. We have upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry.

In-depth verification and validation testing of the Innatal assay, using >1000 samples, was conducted as prescribed by multiple peer-reviewed guidelines.^1,2,3

What did we find?

The Innatal Prenatal Screen is:

Precise – Agreement of >99% for repeatability and reproducibility⁴

Accurate – High concordance with known clinical outcomes⁴

Sensitive – Proven to identify affected fetuses with >99% sensitivity⁴

Specific – Proven to rule-out unaffected fetuses with >99% specificity⁴

Data Summary Sheet

A detailed summary of our verification and validation results.

Have questions?

Dive deeper on how this data uniquely impacts your practice by contacting us. We’ll give you direct access to our lab team.

References

1. Jennings et al. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-55.
2. Lacbawan et al. Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array. Arch Pathol Lab Med. 2012;136(1):14-9.
3. Rehm et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-47.
4. Progenity, Inc. Data on file.